BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vahabnezhad E, Rabizadeh S, Dubinsky MC. A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2014;20:606-613. [PMID: 24552827 DOI: 10.1097/mib.0000000000000003] [Cited by in Crossref: 41] [Cited by in F6Publishing: 12] [Article Influence: 5.9] [Reference Citation Analysis]
Number Citing Articles
1 van Rheenen H, van Rheenen PF. Long-Term Efficacy of Anti-Tumor Necrosis Factor Agents in Pediatric Luminal Crohn's Disease: A Systematic Review of Real-World Evidence Studies. Pediatr Gastroenterol Hepatol Nutr 2020;23:121-31. [PMID: 32206624 DOI: 10.5223/pghn.2020.23.2.121] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
2 Day AS. Re: American Gastroenterological Association Institute Guideline on therapeutic drug monitoring in inflammatory bowel disease. Transl Pediatr 2018;7:11-3. [PMID: 29441278 DOI: 10.21037/tp.2017.12.03] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Hyams JS, Kugathasan S, Dubinsky MC. Combination Therapy in Pediatric Inflammatory Bowel Disease: Yes, No, Maybe. Inflamm Bowel Dis 2017;23:1774-6. [PMID: 28837525 DOI: 10.1097/MIB.0000000000001206] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
4 Hemperly A, Vande Casteele N. Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease. Clin Pharmacokinet 2018;57:929-42. [PMID: 29330783 DOI: 10.1007/s40262-017-0627-0] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 13.3] [Reference Citation Analysis]
5 Herfarth HH, Kappelman MD, Long MD, Isaacs KL. Use of Methotrexate in the Treatment of Inflammatory Bowel Diseases. Inflamm Bowel Dis 2016;22:224-33. [PMID: 26457382 DOI: 10.1097/MIB.0000000000000589] [Cited by in Crossref: 61] [Cited by in F6Publishing: 18] [Article Influence: 10.2] [Reference Citation Analysis]
6 Guberna L, Nyssen OP, Chaparro M, Gisbert JP. Frequency and Effectiveness of Empirical Anti-TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review with Meta-Analysis. J Clin Med 2021;10:2132. [PMID: 34069295 DOI: 10.3390/jcm10102132] [Reference Citation Analysis]
7 Nuti F, Fiorino G, Danese S. Adalimumab for the treatment of pediatric Crohn’s disease. Expert Review of Clinical Immunology 2015;11:963-72. [DOI: 10.1586/1744666x.2015.1072048] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
8 Dillman JR, Dehkordy SF, Smith EA, DiPietro MA, Sanchez R, DeMatos-Maillard V, Adler J, Zhang B, Trout AT. Defining the ultrasound longitudinal natural history of newly diagnosed pediatric small bowel Crohn disease treated with infliximab and infliximab-azathioprine combination therapy. Pediatr Radiol 2017;47:924-34. [PMID: 28421251 DOI: 10.1007/s00247-017-3848-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
9 Djurić Z, Šaranac L, Budić I, Pavlović V, Djordjević J. Therapeutic role of methotrexate in pediatric Crohn's disease. Bosn J Basic Med Sci 2018;18:211-6. [PMID: 29338679 DOI: 10.17305/bjbms.2018.2792] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
10 Ruuska T, Küster P, Grahnquist L, Lindgren F, Wewer AV. Efficacy and safety of granulocyte, monocyte/macrophage adsorptive in pediatric ulcerative colitis. World J Gastroenterol 2016; 22(17): 4389-4396 [PMID: 27158208 DOI: 10.3748/wjg.v22.i17.4389] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
11 Pastore S, Naviglio S, Canuto A, Lepore L, Martelossi S, Ventura A, Taddio A. Serious Adverse Events Associated with Anti-Tumor Necrosis Factor Alpha Agents in Pediatric-Onset Inflammatory Bowel Disease and Juvenile Idiopathic Arthritis in A Real-Life Setting. Paediatr Drugs 2018;20:165-71. [PMID: 29214394 DOI: 10.1007/s40272-017-0267-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
12 Rolandsdotter H, Marits P, Sundin U, Wikström AC, Fagerberg UL, Finkel Y, Eberhardson M. Serum-Infliximab Trough Levels in 45 Children with Inflammatory Bowel Disease on  Maintenance Treatment. Int J Mol Sci 2017;18:E575. [PMID: 28272355 DOI: 10.3390/ijms18030575] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
13 Herfarth HH. Methotrexate for Inflammatory Bowel Diseases - New Developments. Dig Dis 2016;34:140-6. [PMID: 26981630 DOI: 10.1159/000443129] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
14 Jung D, Lee S, Jeong I, Oh SH, Kim KM. Short-Term Outcome of Infliximab Therapy in Pediatric Crohn's Disease: A Single-Center Experience. Pediatr Gastroenterol Hepatol Nutr 2017;20:236-43. [PMID: 29302505 DOI: 10.5223/pghn.2017.20.4.236] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]